| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2006-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008542261-A |
| titleOfInvention |
Composition comprising humanized antibody HBBK4 for cancer treatment and use thereof |
| abstract |
The present invention relates to a pharmaceutical composition comprising a humanized anti-4-1BB antibody together with a pharmaceutically acceptable carrier for treating cancer by inducing an increase in CD11 + CD8 + T cells and IFN-γ and inhibiting cancer cell proliferation. And its use. Therefore, it is useful for the prevention or treatment of cancer without side effects. [Selection] Figure 1 |
| priorityDate |
2005-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |